Karyopharm Therapeutics Long Term Debt

Karyopharm Therapeutics's long-term debt stands at $210M as of June 2026. That compares with $93M in the prior-year period — up 130.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Karyopharm Therapeutics reported $210M in long-term debt versus $93M a year earlier — a 130.0% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $93M in the prior-year period — up 130.0% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Karyopharm Therapeutics's long-term debt evolved across reporting periods, while the comparison chart places KPTI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, long-term debt is commonly used to spot outliers. Karyopharm Therapeutics's reading of $210M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.